Novavax | NVAX - Equity Capital And Reserves


Novavax reported $-144.76M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Adma Biologics USD 390.32M 86.99M Mar/2026
Agenus USD -221.22M 49.89M Mar/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
BioCryst Pharmaceuticals USD -553.84M 434.69M Mar/2026
Cassava Sciences USD 68.14M 6.26M Mar/2026
Geron USD 229.11M 3.24M Mar/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
MannKind USD -59.2M 8.17M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
Moderna USD 6.76B 647M Jun/2026
Novartis USD 38.93B 7.2B Mar/2026
Novavax USD -144.76M 17.01M Mar/2026
Pfizer USD 85.19B 4.91B Jun/2026
Sanofi EUR 69.57B 3.24B Jun/2026
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
TG Therapeutics USD 583.13M 64.89M Mar/2026